Dehbashi Zahra, Moosazadeh Mahmood, Afshari Mahdi
Department of Gynecology, Zabol University of medical Sciences, Zabol, Iran.
Health Sciences Research Center, Faculty of Health, Mazandaran University of Medical Sciences, Sari, Iran.
Mater Sociomed. 2016 Jul 24;28(4):271-273. doi: 10.5455/msm.2016.28.271-273.
Each year, more than forty million abortions are occurred whole of the world. Misoprostol is a prostaglandin analogue with a strong uterotonic effect. The present study aimed to compare the efficacy of Misoprostol in first trimester abortion through two sublingual and vaginal routes of administration.
This randomized clinical trial was conducted on 52 consecutive women in first trimester candidate for pregnancy termination because of fetal IUFD or missed abortion in sonography reports. The patients were hospitalized and then randomly assigned to receive sublingual Misoprostol (400 µg, n 27) or vaginal Misoprostol (400 µg placed in posterior fornix, n = 25).
None of the pregnant in the sublingual group developed complete abortion at the end of follow-up time, while 36% of women inducted with vaginal misoprostol experienced complete abortion indicating a intergroup significant difference (p = 0.001). Compared with vaginal group, those women in sublingual group experienced more complications including diarrhea (22.2% versus 20.0%), nausea and vomiting (22.2% versus 0.0%), and abdominal pain (3.7% versus 0.0%).
The use of Misoprostol in vaginal route results in more abortion completeness as well as lower complication rate as compared to sublingual prescription of the drug.
每年全球有超过四千万例堕胎发生。米索前列醇是一种具有强烈子宫收缩作用的前列腺素类似物。本研究旨在比较米索前列醇通过舌下和阴道两种给药途径用于孕早期流产的疗效。
这项随机临床试验对52名因超声检查报告显示胎儿宫内死亡或稽留流产而处于孕早期且计划终止妊娠的连续女性进行。患者住院后，随机分配接受舌下含服米索前列醇（400微克，n = 27）或阴道放置米索前列醇（400微克置于后穹窿，n = 25）。
随访结束时，舌下含服组无一例孕妇完全流产，而阴道使用米索前列醇引产的女性中有36%完全流产，表明组间存在显著差异（p = 0.001）。与阴道给药组相比，舌下含服组女性出现更多并发症，包括腹泻（22.2%对20.0%）、恶心和呕吐（22.2%对0.0%）以及腹痛（3.7%对0.0%）。
与舌下给药相比，阴道使用米索前列醇导致更高的流产完全率以及更低的并发症发生率。
